Summary
This document outlines the NEXUS-Neuro 2026–2056: A Thirty-Year Scientific Roadmap, authored by Marie Seshat Landry, CEO and Founder of Landry Industries Inc., located in Moncton, New Brunswick, Canada. It presents a comprehensive, forward-looking research proposal detailing a six-phase program focused on neurovascular ex vivo support, physiological maintenance, and conditional long-term embodiment through robotics and drones. Operating at Technology Readiness Level 1-2, the proposal establishes strict scope limits, emphasizing that no part of the work constitutes medical advice or claims current human brain sustainment, ensuring all biological work adheres to institutional animal-care, research-ethics, and regulatory approvals.
The core architectural concept of NEXUS-Neuro rests on a closed-loop neurovascular support platform wrapped in dual control paths: an advisory artificial intelligence path that predicts and explains, and an authoritative deterministic safety path that exclusively acts on critical system faults. The programme explicitly separates three distinct outcomes to prevent logical leaps between stages: biological viability ensuring cells and tissue stay alive, functional preservation measured via electrophysiology and validated tasks, and the preservation of consciousness and personal identity. By prioritizing ground-based brain support connected via secure neural links to remote vehicles, the architecture intentionally bypasses the extreme physical risks of flight such as crash, vibration, and thermal shifts.
Structured across six five-year phases running from 2026 to 2056, the roadmap utilizes rigorous go/no-go gates to govern progression. Phase 1 focuses on non-biological bench foundations, fault libraries, and digital twins, culminating in Gate G1. Subsequent phases progressively introduce vascularised organoids and small-animal perfusion models in Phase 2, extend large-scale in-situ animal brain support from hours to days in Phase 3, validate weeks-scale autonomous support in Phase 4, establish clinical bridges and legal frameworks in Phase 5, and finally approach conditional human continuation and remote telepresence embodiment in Phase 6. Each phase mandates independent laboratory replication and strict pre-registered verification metrics.
The roadmap establishes an extensive scientific baseline by reviewing existing literature and clinical milestones up to October 2026, including developments in brain-computer interfaces like Paradromics and Neuralink, warm organ perfusion systems like OrganOx metra and TransMedics OCS Liver, and historical pig brain perfusion studies such as BrainEx and EPCC. Technical specifications detail exact physiological parameters for a human brain, calculating a mass of approximately 1,350 to 1,400 grams, a resting cardiac output share of roughly fifteen percent, a mean cerebral blood flow of 50 milliliters per 100 grams per minute, and an oxygen consumption rate of approximately 50 milliliters per minute. Daily consumables, oxygen delivery margins, and perfusate composition classes are rigorously mapped out to ensure structural viability.
Ethical, legal, and risk frameworks form a vital pillar of the document, aligning with Canada's 2023 clinical definition of death as the permanent cessation of brain function. The proposal introduces an evidence ladder with explicit stop rules to handle emergent neural activity in animal preparations, mandating immediate pauses or independent board reviews upon encountering complex awareness markers. Safeguards ensure that human continuation is strictly opt-in, non-transferable via substitute decision-makers, and fully reversible, allowing participants to retain complete legal personhood, data ownership, and property rights without depending on the survival of a single corporate entity.
Financial planning, resourcing, and risk management are systematically addressed through a staged budget scaling from two to four million Canadian dollars in Phase 1 up to three hundred million dollars in Phase 6, alongside funding routes like NRC IRAP, NBIF, and NFRF. A detailed risk register outlines fourteen tracked risks, categorizing microvascular no-reflow, intracranial pressure, sterility loss, and sensor drift as critical hazards with robust mitigations. The document concludes with an actionable twelve-month implementation plan for Year 1, detailing milestones for defining requirements, building fluid loops, implementing data pipelines, and running continuous bench campaigns.
Researchers, biomedical engineers, bioethicists, and regulatory affairs professionals working in neuro-engineering, critical care medicine, and organ preservation will find this roadmap exceptionally useful. It offers a transparent, methodologically rigorous blueprint that bridges speculative neuroscience with concrete, testable engineering milestones, ensuring that long-term technological ambitions remain strictly tethered to empirical verification, safety protocols, and ethical governance.
FAQ
What is the primary objective of the NEXUS-Neuro programme?
The programme aims to develop a closed-loop neurovascular support platform over a thirty-year span, advancing from non-biological perfusion benches toward whole-brain functional preservation and remote robotic embodiment under strict safety gates.
How does the system architecture handle automated safety versus AI control?
The system utilizes an AI advisory path that predicts, explains, and proposes actions, while an authoritative deterministic safety controller alone executes automatic interventions on listed critical faults.
What legal framework does the document reference regarding brain function and death?
It aligns with Canada's 2023 clinical guideline defining death as the permanent cessation of brain function, framing sustained brain function after bodily failure as continuation rather than resuscitation after death.
What are the core phases of the 30-year roadmap?
The roadmap consists of six five-year phases: Foundations (2026-2030), Neurovascular Models (2031-2035), Whole-Brain Support (2036-2040), Weeks-Scale Support (2041-2045), Clinical Bridges (2046-2050), and Conditional Continuation and Embodiment (2051-2056).
What are the primary physiological requirements for human brain perfusion?
The pod must deliver about 50 mL of oxygen per minute to approximately 1.4 kg of tissue, maintaining normothermic conditions at 37 degrees Celsius with continuous monitoring of pressure, flow, blood gases, and chemistry.
